HEALY JAMES 4

What happened

• James Healy, a director of BioAge Labs, received a derivative award covering 22,000 shares on 2026-06-10. The award shows an acquisition price of $0.00 (i.e., no cash paid at grant). This is a grant/award (not an open-market buy or sale).

Key details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (appears timely).
• Reported consideration: $0.00 per share (derivative award).
• Shares involved: 22,000 shares granted.
• Shares owned after transaction: Not specified in the Form 4 provided.
• Footnote: The option award vests on the earlier of (i) the date of the issuer’s next annual meeting or (ii) the one-year anniversary of the grant date, subject to Healy’s continued service.
• No 10b5-1 plan, tax-withholding sale, or immediate sale reported.

Context

• This is a compensation/award transaction (a derivative option grant) rather than a market purchase or sale, so it represents a grant of potential future equity subject to vesting. The footnote indicates the grant vests within a year (or sooner at the next annual meeting) if the director remains in service.